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surface area (BSA) can be estimated in several ways for economic
evaluations. A review of 20 recent National Institute for Health and
Care Excellence appraisals showed that 17 of them took the mean
weight or BSA of patients, 2 costed the individual patient data from
trials, and 2 ﬁtted a distribution to patient-level data. Objectives:
To investigate the estimated drug costs using different methodologies
to account for patient characteristics for pharmaceuticals with a
weight- or BSA-based posology. The secondary objective was to
explore the suitability of general population data as a proxy for
patient-level data. Methods: Patient-level data were pooled from
three clinical trials and used to calculate a hypothetical cost per
administration of eight licensed pharmaceuticals, applying the three
methods used in recent National Institute for Health and Care
Excellence appraisals. The same analysis was performed using data
from the Health Survey for England (in place of patient-level data) toee front matter Copyright & 2016, International S
r Inc. This is an open access article under the CC
ons.org/licenses/by-nc-nd/4.0/).http://dx.doi.org/
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ndence to: Anthony J. Hatswell, BresMed, North Chinvestigate the validity of using general population data as a sub-
stitute for patient-level data. Results: Compared with using patient-
level data from clinical trials, the mean patient characteristics (weight
or BSA) led to an underestimation of drug cost by 6.1% (range þ1.5%
to 25.5%). Fitting a distribution to patient-level data led to a
mean difference of þ0.04%. All estimates were consistent using
general population data. Conclusions: Estimation of drug costs in
health economic evaluation should account for the distribution in
weight or BSA to produce accurate results. When patient data
are not available, general population data may be used as an
alternative.
Keywords: cost-effectiveness, drug costs, health technology appraisal,
method of moments, micro-costing.
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Cohort-based health economic models typically consider the
“average” patient to be a representative of the population of
interest. When the posology for the dosing of drugs is based on
weight or body surface area (BSA), it is common for the costs of
administering a single dose to be based on the weight or BSA of
the average patient. Using the characteristics of the average
patient, however, does not take into account the distribution
seen in the patient population.
We reviewed 60 recent single technology appraisals of the
National Institute for Health and Care Excellence, ﬁnding 20 with
drugs dosed on the basis of weight or BSA when the method of
costing is identiﬁed. Seventeen of them calculated costs on the
basis of the mean weight or mean BSA, two used patient data
costed individually, and one used a parametric distribution ﬁtted
to patient-level data. In the review, only two academic groups(Liverpool Evidence Review Group and the School of Health and
Related Research) raised the issue of inappropriate costing. This
review shows that not only are most analyses using an inaccu-
rate method to estimate drug costs, but this was also rarely
challenged by economic assessors. Given drug acquisition costs
are often one of the key determinants of cost-effectiveness,
accurately estimating these is fundamental to the integrity of
economic evaluation in health care.
Our objective was to examine the impact of different methods
of costing treatments on the quantiﬁcation of drug costs per
administration of interventions with weight- or BSA-based dos-
ing. To achieve this, we used patient-level data from three
clinical trials to calculate the costs of eight drugs on the basis
of either weight or BSA. We used three approaches: the para-
meter mean (termed the parameter mean approach); costing
of patients individually and then taking the average cost (trial
patient costing); and ﬁtting a parametric distribution to weight orociety for Pharmacoeconomics and Outcomes Research (ISPOR).
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costing).
As the trial patient costing and ﬁtted-distribution costing
approaches required patient-level data, we replicated the analy-
sis using publicly available general population data to establish
whether general population data can be a substitute in the
absence of patient-level data.Methods
Data Sources
Patient-level data from the following three clinical studies were
obtained to allow the analysis of different disease areas to
enhance the generalizability of our ﬁndings: CA184-024, which
enrolled 681 patients with advanced melanoma [1]; AI444-040, an
open-label trial of 211 patients with chronic hepatitis C [2]; and
CA180-034, a dose-ranging study of 670 patients with chronic
myeloid leukemia [3]. The data sets were analyzed separately,
before being pooled to provide a larger sample size.
The general population data set used in the analysis was
derived from the Health Survey for England (HSE), which collects
health and demographic data from randomly selected house-
holds in England [4]. Only adults aged 31 to 80 years with
nonmissing values were included because they represented the
pooled clinical trial data set.
Eight drugs that were granted a marketing authorization
within the last 5 years were chosen as examples in our analysis:
ipilimumab, cabazitaxel, ustekinumab, brentuximab vedotin,
cetuximab, clofarabine, panitumumab, and cladribine. These
are patented medicines that span a range of disease areas and
are dosed using various posologies on the basis of either weight
or BSA. The dosing for each of these drugs was taken from the
European Summary of Product Characteristics, and prices were
taken from the Monthly Index of Medical Specialities (January
2015) (Table 1) [5]. Three of the drugs (ipilimumab, cetuximab,
and panitumumab) are available in two linearly priced vial sizes;
in our analysis the smaller size was used for simplicity, because
the wastage would have been the same if the larger vial was
used. When dosing was based on BSA, it was derived from
patients’ height and weight using the Du Bois formula (the most
widely used estimation formula) [6].
Costing Methodologies
The parameter mean approach uses the arithmetic mean of the
weight or BSA of the pooled trial data set and calculates theTable 1 – Summary of the drugs included in the analysis
Product Dosing parameter Dose
Brentixumab vedotin Weight 1.8 mg/k
Cabazitaxel BSA 25 mg/m
Cetuximab BSA 250 mg/m
Cladribine Weight 1.2 mg/k
Clofarabine BSA 52 mg/m
Ipilimumab Weight 3 mg/kg
Panitumumab Weight 6 mg/kg
Ustekinumab Weight o100 kg: 45
Z100 kg: 90
BSA, body surface area.number of vials required to administer each dose for this hypo-
thetical mean patient (rounded up to the nearest whole vial).
The trial patient costing approach involves costing the num-
ber of whole vials (and thus the cost) required for each patient,
before taking the mean of the individual costs (thus incorporating
the distribution in patient characteristics observed in the trial).
This approach was used as the reference because it essentially
represents the “true” drug cost that would be incurred given the
individual characteristics of the trial participants.
Finally, the ﬁtted-distribution approach involves ﬁtting a
parametric distribution to the cumulative density of patient
weight or BSA. Distribution parameters were estimated using a
method of moments technique [7].Results
The pooled trial data set contained the weight and height of 1326
patients, whereas the HSE data set contained those of 5427
individuals between the ages of 31 and 80 years (inclusive). The
results of our analysis were consistent when we analyzed each of
the three clinical trials separately and when we pooled the trial
data. Here, we focus on the pooled data.
The costs of one administration of each drug using trial
patient costing, parameter mean approach, and ﬁtted-
distribution costing are presented in Table 2, using the pooled
trial data and the HSE data. For all but one of the drugs included
(cladribine), the parameter mean approach led to an under-
estimate of the true drug cost compared with trial patient costing.
The scale of error in drug-cost estimation ranged from a 1.5%
overestimation of costs with cladribine to a 9.6% underestimation
of costs with ustekinumab.
The differences between trial patient costing and ﬁtted-
distribution costing were small, ranging from a 0.03% underestima-
tion with ipilimumab to a 0.4% overestimation with ustekinumab.
On comparing the results of trial patient costing with a
distribution ﬁtted to HSE data, we found the results to be also
consistent, and errors were much smaller than those associated
with the parameter mean approach. We found that using the HSE
data led to slight overcostings for treatments dosed on the basis
of weight and undercostings for treatments dosed on the basis
of BSA.Discussion
The results of the analysis show that using mean patient
characteristics (be it weight or BSA) is likely to produce inaccurate.
Products available (mg) Cost per vial (£)
g 50 2,500
2 60 3,696
2 100 178
500 891
g 10 160
2 20 1,316
50 3,750
200 15,000
100 379
400 1,517
mg 45 2,147
mg
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V A L U E I N H E A L T H ] ( 2 0 1 6 ) ] ] ] – ] ] ] 3estimates of drug costs—this was consistent for treatments
based on both weight and BSA. Subsequent resource allocation
decisions could be ﬂawed: either by overestimating costs and
rejecting cost-effective technologies or by underestimating costs
and accepting cost-ineffective technologies. In our analysis, the
parameter mean approach led to costs that were different from
the “true” cost (on the basis of patient-level trial data) by more
than 3% for six of the eight drugs analyzed.
The impact of inappropriate drug costing is illustrated in the
National Institute for Health and Care Excellence technology
appraisal TA319 (ipilimumab in previously untreated advanced
melanoma), in which the incremental cost-effectiveness ratio
was presented using both the ﬁtted-distribution technique and
the parameter mean approach. The parameter mean approach
resulted in a 4.4% lower cost per dose of ipilimumab, with
incremental cost-effectiveness ratios reducing from £47,899 to
£45,935 versus dacarbazine and from £28,642 to £20,892 versus
vemurafenib (for which incremental differences were lower,
making variations in drug cost more inﬂuential) [8].
Whether the use of the parameter mean approach under-
estimates or overestimates the cost of a product depends funda-
mentally on whether the number of vials required to treat the
mean patient is greater or lesser than the mean number of vials
required to treat across all patients in the trial. In turn, this
depends on the mean patient weight or BSA, the vial size, and the
distribution of patient weight or BSA. If the vial size of a drug
allows the mean patient to be treated with very little wastage of
drug, then the parameter mean approach may likely under-
estimate the drug cost. In contrast, if the vial size is such that
there is substantial wastage in treating the mean patient (as was
the case in our analysis for cladribine), then the parameter mean
approach may overestimate the drug cost. This, however, also
depends on the distribution of weight or BSA. In the data sets we
analyzed, there was a right skew in the weight or BSA distribu-
tions. For seven of the eight drugs we analyzed, the longer right
tail of the distributions meant that the mean number of vials per
patient required to treat the population was greater than the
number of vials required by the mean patient. This suggests that
pharmaceutical companies may at present be basing vial sizes on
mean patient weight or BSA, such that there is little wastage
when treating the mean patient. This does not necessarily mean
that patients at extremes of the distribution are being treated
with more wastage; it rather signals that taking account of these
patients in cost calculations is likely to increase the quantity of
vials estimated to be required when there is a right-skewed
distribution, and when the mean patient can be treated with
little wastage. Developing methods for identifying how to most
efﬁciently size vials to reduce wastage is a separate question that
requires further research.
This analysis focuses only on the cost of one administration of
treatment (for simplicity)—any cost differential would be com-
pounded over the duration of treatment. A relatively small
costing error per dose could therefore amount to considerable
inaccuracy if administration is frequent and continuous. Our
analyses, however, are relevant only for treatments that are
dosed on a variable scale (according to weight or BSA)—the issue
that we have analyzed is not relevant for treatments dosed on a
ﬁxed scale because for these treatments there is no distribution
to consider.
Use of General Population Data
The primary analyses conducted relied on the availability of
patient-level data; the cost estimates using the HSE data set,
however, showed results consistent with those of the trial data
set. Although the use of HSE data led to slight overcostings for
treatments based on weight, and undercostings for treatments
V A L U E I N H E A L T H ] ( 2 0 1 6 ) ] ] ] – ] ] ]4based on BSA, any differences were under 1% in all cases. We
suggest that using HSE data is a preferable alternative to the
parameter mean approach when patient-level data from relevant
trials are not available or accessible.
Estimation of Parameter Distributions
The results of this analysis are less indicative of whether a ﬁtted
distribution or the individual patient-level data are optimal.
Although the results are similar between the two methods, we
would suggest that a distribution would be the most appropriate.
A trial is, by deﬁnition, only a sample of the eligible patients—
unless it is extremely large; it is unlikely to be perfectly repre-
sentative of the population of interest, particularly concerning
the extreme ends of the parameter range. Fitting a distribution
would be less sensitive to the inclusion (or exclusion) of outliers
in any given sample.
Limitations of the Analysis
The main assumption and limitation of this analysis is that
potential vial sharing was not considered. In some markets (e.g.,
Germany), however, vial sharing is absolutely forbidden, whereas
with many new (and niche) treatments, it simply is not practical.
For more commonly administered treatments in some markets,
there is the potential for a degree of vial sharing to occur if
patients are treated in the same center, or if administrations are
coordinated. The effect of vial sharing would be to decrease drug
wastage (and thus cost) regardless of the costing approach used.
In addition, our analysis has been performed on conditions
that affect adults, are not correlated with height or weight, and
that have a broadly similar male to female ratio. If a condition is
much more prevalent in one sex, is linked to weight, or affects
children/adolescents, general population data may need to be
further stratiﬁed, or alternative data sources sought if patient-
level trial data are not available to estimate treatment costs.
Alternative analytical techniques may also be required if weight
and height were expected to change over time in affected
patients. That said, our analysis included three distinct diseases
and results were consistent, suggesting that our ﬁndings have
good generalizability.Conclusions
Our analysis has demonstrated that for treatments dosed on a
variable scale (e.g., by weight or BSA), the use of mean weight or
BSA is expected to result in inaccurate estimates of drug costs.In our analyses, using mean weight or BSA generally led to an
underestimation of drug costs. We also found that open access
data from the general population can act as a surrogate when
patient-level data from relevant trials are not available, and
the disease population has no speciﬁc characteristics that
distinguishes it from the general population.
Whether individual patient-level data are used or a distribu-
tion ﬁtted to this, economic models (particularly in health
technology assessment) should take into account variability in
patient characteristics when costing treatments. Modeling guide-
lines are not prescriptive regarding the method used for the
costing of drugs, which may be an important oversight.Acknowledgments
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